U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H9NOSe
Molecular Weight 274.18
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EBSELEN

SMILES

O=C1N([Se]C2=CC=CC=C12)C3=CC=CC=C3

InChI

InChIKey=DYEFUKCXAQOFHX-UHFFFAOYSA-N
InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H

HIDE SMILES / InChI

Molecular Formula C13H9NOSe
Molecular Weight 274.18
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ebselen is a small molecule mimic and inducer of glutathione peroxidase activity and possesses antioxidant and anti-inflammatory properties. This drug has been investigated in phase II clinical trials for the treatment of Meniere's disease, bipolar disorder and in the prevention of hearing loss. Besides, experiments on mice have shown that ZIKV infection could be on the list for potential use of ebselen. It alleviates testicular pathology in mice with Zika virus infection and prevents its sexual transmission. Ebselen has various mechanisms of action. It binds to the N-terminal domain of soluble epoxide hydrolase and chemically reacts with the enzyme to quickly and irreversibly inhibit one of the enzymes' activity: phosphatase (Nterm-phos). Besides, ebselen inhibits inositol monophosphatase and thus exhibits lithium-like on human central nervous system (CNS) function. In addition, ebselen inhibits the G4 isoform of acetylcholinesterase. It is a well-known relationship between the cholinergic system and learning, memory and other common cognitive processes, thus ebselen can be studied for the treatment of memory impairment diseases.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P34913|||Q9HBJ2
Gene ID: 2053.0
Gene Symbol: EPHX2
Target Organism: Homo sapiens (Human)
550.0 nM [Ki]
Target ID: P22303|||Q53F46
Gene ID: 43.0
Gene Symbol: ACHE
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
30.3 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
70.3 ng/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
67.5 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
83.4 ng/mL
1600 mg single, oral
dose: 1600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
546.31 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
710.1 ng × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
883.15 ng × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
992.64 ng × h/mL
1600 mg single, oral
dose: 1600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.42 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
14.4 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
12.1 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
16.7 h
1600 mg single, oral
dose: 1600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EBSELEN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
PZ-51 (Ebselen) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity.
1992 Aug 18
Molecular actions of ebselen--an antiinflammatory antioxidant.
1995 Oct
Cellular factors as alternative targets for inhibition of HIV-1.
1997 Feb
Inhibition of ebselen on aflatoxin B(1)-induced hepatocarcinogenesis in Fischer 344 rats.
2000 Dec
Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide.
2000 Feb 18
Anti-oxidant ebselen causes the resolution of experimentally induced hepatic fibrosis in rats.
2001 Nov
Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species.
2002 Jun 7
Functionalized alkyl and aryl diselenides as antimicrobial and antiviral agents: synthesis and properties.
2003 Dec
An inducible nitric oxide synthase-luciferase reporter system for in vivo testing of anti-inflammatory compounds in transgenic mice.
2003 Jun 15
Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes.
2003 Nov 1
Renal and hepatic ALA-D activity and selected oxidative stress parameters of rats exposed to inorganic mercury and organoselenium compounds.
2004 Jan
Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain.
2005 Jul
Up-regulation of heme oxygenase provides vascular protection in an animal model of diabetes through its antioxidant and antiapoptotic effects.
2006 Dec
Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen.
2006 Jul
Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species.
2006 Jul 1
Oral pretreatment with ebselen enhances heat shock protein 72 expression and reduces myocardial infarct size.
2006 Nov
Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.
2006 Oct 1
Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake.
2006 Sep
The protective mechanism of antioxidants in cadmium-induced ototoxicity in vitro and in vivo.
2008 Jul
Mitochondria-derived reactive oxygen species mediate heme oxygenase-1 expression in sheared endothelial cells.
2009 Apr
A superoxide anion-scavenger, 1,3-selenazolidin-4-one suppresses serum deprivation-induced apoptosis in PC12 cells by activating MAP kinase.
2011 Dec 15
Antimalarial screening via large-scale purification of Plasmodium falciparum Ca2+-ATPase 6 and in vitro studies.
2013 Nov
The seleno-organic compound ebselen impairs mitochondrial physiology and induces cell death in AR42J cells.
2014 Sep 17
Patents

Patents

Sample Use Guides

Bipolar Disorder: ebselen capsules each containing 200mg taken orally twice a day for 3 weeks Meniere's Disease: 200, 400 or 600 mg of drug bid po x 21d hearing loss: 400 mg twice daily
Route of Administration: Oral
ebselen at concentrations equal or higher than 10 µM inhibited the activity of cortical and hippocampal G4/acethylcholinesterase (AChE), but not G1/AChE isoform.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:11:21 GMT 2023
Edited
by admin
on Sat Dec 16 17:11:21 GMT 2023
Record UNII
40X2P7DPGH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EBSELEN
INN   MART.   MI  
INN  
Official Name English
NSC-639762
Code English
2-PHENYL-1,2-BENZISOSELENAZOL-3(2H)-ONE
Systematic Name English
SPI-1005
Code English
ebselen [INN]
Common Name English
EBSELEN [JAN]
Common Name English
EBSELEN [MI]
Common Name English
DR-3305
Code English
EBSELEN [MART.]
Common Name English
NSC-757883
Code English
DR3305
Code English
Ebselen [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1323
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
NCI_THESAURUS C275
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C65503
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
SMS_ID
100000080483
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
CHEBI
77543
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
FDA UNII
40X2P7DPGH
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
CAS
60940-34-3
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
EPA CompTox
DTXSID7045150
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
NSC
639762
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
NSC
757883
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
MESH
C042986
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
INN
5475
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
WIKIPEDIA
EBSELEN
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
DRUG BANK
DB12610
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
EVMPD
SUB06439MIG
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
MERCK INDEX
m4803
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY Merck Index
PUBCHEM
3194
Created by admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY